COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR
Open Access
- 4 July 2016
- journal article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 7 (1), 12044
- https://doi.org/10.1038/ncomms12044
Abstract
Oestrogen receptor α (ERα) antagonists are used in endocrine therapies for ERα-positive (ERα+) breast cancer patients. Unfortunately the clinical benefit is limited due to intrinsic and acquired drug resistance. Here using integrated genomic and functional studies, we report that amplification and/or overexpression of COPS5 (CSN5/JAB1) confers resistance to tamoxifen. Amplification and overexpression of COPS5, a catalytic subunit of the COP9 complex, is present in about 9% of the ERα+ primary breast cancer and more frequently (86.7%, 26/30) in tamoxifen-refractory tumours. Overexpression of COPS5, through its isopeptidase activity, leads to ubiquitination and proteasome-mediated degradation of NCoR, a key corepressor for ERα and tamoxifen-mediated suppression of ERα target genes. Importantly, COPS5 overexpression causes tamoxifen-resistance in preclinical breast cancer models in vitro and in vivo. We also demonstrate that genetic inhibition of the isopeptidase activity of COPS5 is sufficient to re-sensitize the resistant breast cancer cells to tamoxifen-treatment, offering a potential therapeutic approach for endocrine-resistant breast cancer patients.This publication has 51 references indexed in Scilit:
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused UpdateJournal of Clinical Oncology, 2014
- Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic reviewCancer Treatment Reviews, 2013
- Improving Endocrine Therapy for Breast Cancer: It's Not That SimpleJournal of Clinical Oncology, 2013
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- Endocrine Therapy of Breast CancerCurrent Medicinal Chemistry, 2011
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Minireview: Nuclear Receptors and Breast CancerMolecular Endocrinology, 2008
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceEndocrine Reviews, 2008
- Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cellsJournal of Molecular Endocrinology, 2008
- Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancerEndocrine-Related Cancer, 2005